Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ariad Pharmaceuticals, Inc.    ARIA

Delayed Quote. Delayed  - 08/24 03:34:00 pm
10.66 USD   +0.57%
08/01 ARIAD PHARMACEU : PDL BioPharma Completes Second Tranche Payment Und..
07/28 ARIAD PHARMACEU : beats 2Q profit forecasts
07/28 ARIAD PHARMACEU : Reports Second Quarter and First Half 2016 Financi..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Ariad Pharmaceuticals, Inc. : ARIA, XOMA, PRAN and NIHD added to NASDAQ Active Stock Watch List at EPR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/31/2013 | 03:15pm CEST

New York, NY - (ACCESSWIRE) - 10/31/2013 - Equity Profile Report initiates its NASDAQ Active Stock Weekly Watch List adding Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), XOMA Corporation (NASDAQ:XOMA), Prana Biotechnology Limited (NASDAQ:PRAN) and NII Holdings Inc. (NASDAQ:NIHD)

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients is currently down (-38.13%) on 26,575,426 shares traded after Ariad suspended sales of cancer pill Iclusig. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) is currently down (-90.81%) from its recent 52-week high, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=ARIA&SubId=AW

XOMA Corporation (NASDAQ:XOMA) a company that discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific is currently up (+4.35%) on 712,280 shares traded after XOMA Corporation announced very encouraging results from two Phase 2 clinical studies that are part of the Company's broad gevokizumab proof-of-concept program. XOMA Corporation (NASDAQ:XOMA) is currently up (+95.78%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about XOMA Corporation (NASDAQ:XOMA)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=XOMA&SubId=AW

Prana Biotechnology Limited (NASDAQ:PRAN) a company that researches and develops therapeutic drugs for the treatment of neurological disorders in Australia is currently up (+1.80%) on 563,051 shares traded after Prana's PBT2 Reversed Memory Loss in Normal Aging. Prana Biotechnology Limited (NASDAQ:PRAN) is currently up (+161.31%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Prana Biotechnology Limited (NASDAQ:PRAN)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=PRAN&SubId=AW

NII Holdings Inc. (NASDAQ:NIHD) a company that through its subsidiaries, provides wireless communication services under the Nextel brand name to businesses and individuals in Mexico, Brazil, Argentina, Peru, and Chile is currently down (-19.58%) on 2,272,972 shares traded after NII Holdings, Inc. Discussed Q3 2013 Results. NII Holdings Inc. (NASDAQ:NIHD) is currently down (-61.3%) from its recent 52-week high, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about NII Holdings Inc. (NASDAQ:NIHD)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=NIHD&SubId=AW

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.equityprofilereport.com/

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARIAD PHARMACEUTICALS, INC
08/11 PDL BIOPHARMA : Completes Second Tranche Payment Under Royalty Transaction with ..
08/08 ARIAD PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
08/01 ARIAD PHARMACEUTICALS : PDL BioPharma Completes Second Tranche Payment Under Roy..
07/28 ARIAD PHARMACEUTICALS : beats 2Q profit forecasts
07/28 ARIAD PHARMACEUTICALS INC : Results of Operations and Financial Condition, Regul..
07/28 ARIAD PHARMACEUTICALS : Reports Second Quarter and First Half 2016 Financial Res..
07/22 ARIAD PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holders,..
07/07 ARIAD PHARMACEUTICALS : Announces Webcast of Its Annual Stockholders Meeting
07/07 ARIAD PHARMACEUTICALS : Biotechnology Equities Under the Scanner - Exelixis, Nov..
07/05 ARIAD PHARMACEUTICALS : to Webcast Conference Call on Second Quarter 2016 Financ..
More news
Sector news : Bio Therapeutic Drugs
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
08/22DJPFIZER : to Acquire Medivation in Deal Worth $14 Billion -- 4th Update
08/22DJPFIZER : to Acquire Medivation in Deal Worth $14 Billion -- 3rd Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
08/23 Under New Structure, ARIAD Growth Opportunities May Be Undervalued
08/23 ARIAD Pharmaceuticals Could Be Benefiting From Prescriber Education
08/12 Ariad Is Worth A Look After Q2 Results
08/09 Market At All-Time Highs, September Can Be A Month Of Consolidation
07/29 BIOTECH FORUM DAILY DIGEST : Biotech Tries To Break Through Upward Resistance Le..
Advertisement
Financials ($)
Sales 2016 191 M
EBIT 2016 -119 M
Net income 2016 -55,1 M
Debt 2016 230 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 11,9x
EV / Sales 2017 9,72x
Capitalization 2 043 M
More Financials
Chart ARIAD PHARMACEUTICALS, INC
Duration : Period :
Ariad Pharmaceuticals, Inc Technical Analysis Chart | ARIA | US04033A1007 | 4-Traders
Full-screen chart
Technical analysis trends ARIAD PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 10,4 $
Spread / Average Target -1,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Paris Panayiotopoulos President, Chief Executive Officer & Director
Alexander John Denner Chairman
Manmeet Singh Soni Chief Financial Officer, Treasurer & Executive VP
Timothy P. Clackson Chief Scientific Officer
Frank G. Haluska Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ARIAD PHARMACEUTICALS,..69.60%2 043
AMGEN, INC.7.44%130 514
GILEAD SCIENCES, INC.-19.49%107 513
CELGENE CORPORATION-4.80%88 371
REGENERON PHARMACEUTIC..-22.52%44 288
VERTEX PHARMACEUTICALS..-19.74%25 023
More Results